Ligand Pharmaceuticals LGND Royalties — Total revenues and income

Other product segments

Similar metrics at other companies

BMRNRoyalty and other revenues — Total revenues

$6.13M-41.6%

BIIBRoyalty and other revenue — Total Revenue

$9.7M-11.8%

GILDRoyalty, contract and other revenues — Total revenues

$14M-74.1%

RPRXIncome from financial royalty assets — Total income and other revenues

$594.99M+10.3%

RGENRoyalty — Revenue (Gross)

$44K+25.7%

INCYProduct royalty revenues — Total revenues

$151.19M+15.7%

Questions, answered.

What is Ligand Pharmaceuticals's royalties — total revenues and income?

Ligand Pharmaceuticals (LGND) reported royalties — total revenues and income of $42.96M in Q1 2026.

How has Ligand Pharmaceuticals's royalties — total revenues and income changed year-over-year?

Ligand Pharmaceuticals's royalties — total revenues and income increased by 56.3% year-over-year, from $27.49M to $42.96M.

What is the long-term trend for Ligand Pharmaceuticals's royalties — total revenues and income?

Over 4 years (2021 to 2025), Ligand Pharmaceuticals's royalties — total revenues and income has grown at a 34.7% compound annual growth rate (CAGR), from $48.93M to $161M.

What does royalties — total revenues and income mean?

This metric represents the aggregate financial inflow generated by the royalties segment, encompassing both direct product royalties and associated milestone or licensing income. It serves as a comprehensive measure of the total economic value captured from the company's portfolio of licensed pharmaceutical assets. Tracking this figure allows investors to assess the overall performance and monetization success of the company's intellectual property partnerships.